Italia markets close in 10 minutes

Axsome Therapeutics, Inc. (AXSM)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
71,37+0,20 (+0,28%)
In data: 11:19AM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente71,17
Aperto70,39
Denaro71,25 x 100
Lettera89,56 x 200
Min-Max giorno69,53 - 72,38
Intervallo di 52 settimane55,02 - 98,40
Volume104.406
Media Volume726.472
Capitalizzazione3,381B
Beta (5 anni mensile)1,10
Rapporto PE (ttm)N/D
EPS (ttm)-5,27
Prossima data utili06 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A123,00
  • GlobeNewswire

    Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

    NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome’s board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice

  • GlobeNewswire

    Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6

    Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern TimeNEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter of 2023 on Monday, Nov. 6, 2023, before the opening of the U.S. financial markets. Axsome’s management team w

  • GlobeNewswire

    Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week

    NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it is joining patient advocacy organizations, including the National Alliance on Mental Illness (NAMI), to promote awareness of the importance of mental health during Mental Illness Awareness Week (MIAW), recognized on Oct. 1-7, 2023. As part of Axsome’s commitment